0.57 USD
▲+0.02+3.92%
盘后 0.58 +4.42%
2026-08-03
市值
$168.87M
市盈率
—
EPS
-0.35
股息率
—
52 周区间
0.48 – 3.07
成交量
4.41M
Beta
0.67
目标价
10.00
52W 低 0.4852W 高 3.07
价格走势
公司简介
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatmen...